R&ED into Samit's GDD organization- a train wreck in the making?

[anonymous]

Not too sure this will work out too well for the organization. Samit has limited to no early development science.

 

[anonymous]

Not too sure this will work out too well for the organization. Samit has limited to no early development science.

Eternal problem in pharma. Comes down to leadership, processes, and culture. Can it work, yes. Will it work…not so clear

 

[anonymous]

Vessey being forced out. Not sure how good this decision is.

 

[anonymous]

Vessey is a rock star in the R&D space. Surprised he lasted as long as he did in a company that abhors innovation. Will buy stock in whatever company he goes to next.

 

[anonymous]

Vessey is a rock star in the R&D space. Surprised he lasted as long as he did in a company that abhors innovation. Will buy stock in whatever company he goes to next.

Ruppert is a smart guy and is very eloquent.
I don’t think he’s a rock star in his current role though. What has come out of his shop during his tenure?? Pretty much nothing.

His group is essentially a black hole that BMS (and Celgene) throws money into and never sees anything come out.

 

[anonymous]

Ruppert is a smart guy and is very eloquent.
I don’t think he’s a rock star in his current role though. What has come out of his shop during his tenure?? Pretty much nothing.

His group is essentially a black hole that BMS (and Celgene) throws money into and never sees anything come out.

did you forget why we charge 80k for grandma's eliquis or something?

 

[anonymous]

Ruppert is a smart guy and is very eloquent.
I don’t think he’s a rock star in his current role though. What has come out of his shop during his tenure?? Pretty much nothing.

His group is essentially a black hole that BMS (and Celgene) throws money into and never sees anything come out.

Samit is a hot mess and will make this group even more nonproductive.

 

[anonymous]

did you forget why we charge 80k for grandma's eliquis or something?

Yup….complete money suck…good riddance

 

[anonymous]

I don't know shit about Rupert, and I never found him particularly impressive during meetings and whatnot, but I think this should be good for the business. Early and Late clinical being in two separate organizations is completely asinine. I still think that non-clinical research belongs in a separate silo, but the handover to full development is ALWAYS a nightmare.

 

[anonymous]

Rupert flushed $650 million down the Dragonfly toilet. Not exactly a genius there. Plenge doesn’t seem much better. I give him 2 years tops till he “retires” also.

 

[anonymous]

Rupert flushed $650 million down the Dragonfly toilet. Not exactly a genius there. Plenge doesn’t seem much better. I give him 2 years tops till he “retires” also.

That’s just the tip of the iceberg!